Effectiveness of neo-adjuvant systemic therapy with trastuzumab for basal HER2 type breast cancer: results from retrospective cohort study of Japan Breast Cancer Research Group (JBCRG)-C03.

Yasuaki SagaraMasahiro TakadaYasuyo OhiShoichiro OhtaniSasagu KurozumiKenichi InoueYoshimasa KosakaMasaya HattoriToshinari YamashitaShintaro TakaoNobuaki SatoHiroji IwataMasafumi KurosumiMasakazu Toi

Published in: Breast cancer research and treatment (2018)

Basal HER2 phenotype showed poor DFS, but equivalent pCR rate after concurrent neo-adjuvant chemotherapy with trastuzumab. A different treatment approach to basal-HER2 type is needed even for cases that achieved adequate clinical response after NAC.

Keyphrases

epidermal growth factor receptor
randomized controlled trial
early stage
metastatic breast cancer
transcription factor
systematic review
stem cells
radiation therapy
tyrosine kinase
combination therapy
young adults
cell therapy